KPV complete guide

KPV is a synthetic tripeptide composed of L-lysine, L-proline and L-valine (Lys-Pro-Val). It is the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) — the 13-amino-acid pituitary hormone derived from proopiomelanocortin (POMC). Published research has progressively established KPV as the “anti-inflammatory minimum sequence” of alpha-MSH: the smallest fragment that retains the parent hormone’s anti-inflammatory activity while losing its pigmentary, melanocortin-receptor-driven effects.

This positions KPV as one of the better-characterised small-peptide anti-inflammatories in the published research literature. The dominant published research lines are in inflammatory bowel disease models (DSS colitis, TNBS colitis, IL-10 KO mice) and in dermal-matrix and mast-cell research. This guide is mechanism-focused: where KPV came from, how it modulates NF-κB intracellularly, why PEPT1-mediated uptake matters, and how it sits inside the multi-compound Klow Blend. Everything is research-frame language. No protocol guidance. No clinical recommendations.

Quick reference — KPV identifiers

Property	KPV
Class	Synthetic tripeptide; alpha-MSH(11–13) C-terminal fragment
Sequence	KPV — Lys-Pro-Val (3 amino acids)
Molecular formula	C16H31N5O4
Molecular weight	357.45 g/mol
CAS	52154-21-1
Origin	Synthetic equivalent of the alpha-MSH C-terminal tripeptide; alpha-MSH itself is endogenous to the mammalian pituitary (POMC cleavage product)
Plasma half-life	Research models: short, on the order of minutes
Vial strengths (TogoPeptide)	5 mg / 10 mg lyophilized; also a component of the Klow Blend (BPC-157 + TB-500 + GHK-Cu + KPV)

Origin and structure — alpha-MSH C-terminal fragment

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide derived from proteolytic cleavage of proopiomelanocortin (POMC) in the pituitary. Classical endocrinology established alpha-MSH as a melanocortin-receptor agonist (MC1R–MC5R) with a defining role in melanin and pigment regulation. Across the late 20th century, however, researchers progressively documented that alpha-MSH also exerted potent anti-inflammatory effects — effects that did not appear to depend on the pigmentary signaling pathway.

Sequence-truncation studies followed. The C-terminal tripeptide — lysine–proline–valine, residues 11–13 of alpha-MSH — was identified as the minimum sequence retaining the anti-inflammatory pharmacophore. Larger N-terminal fragments retained pigmentary activity through the melanocortin receptors; the C-terminal KPV fragment retained the anti-inflammatory activity without the pigmentary signaling. This dissociation of effects is what gives KPV its distinct research profile.

The rationale for studying the truncated tripeptide rather than the full hormone is straightforward in published research: a smaller peptide produces better tissue penetration, is more amenable to oral-bioavailability research designs, and retains the anti-inflammatory activity without engaging melanocortin-receptor pigmentary signaling. KPV thus sits as a well-defined research tool for studying the alpha-MSH anti-inflammatory mechanism in isolation.

Mechanism — anti-inflammatory tripeptide

KPV’s published research footprint converges on a small set of intracellular mechanisms. The dominant pathway is NF-κB modulation, supported by direct cellular uptake via the PEPT1 di/tripeptide transporter.

NF-κB pathway modulation

Published KPV research consistently documents down-regulation of NF-κB nuclear translocation in research-cell-line models [2]. NF-κB is the master pro-inflammatory transcription factor: when activated, it migrates into the nucleus and drives expression of TNF-α, IL-1β, IL-6 and a wider cytokine programme. By reducing NF-κB activation, KPV reduces the downstream inflammatory cytokine output. This is the dominant published mechanism for KPV anti-inflammatory effects across both gut and dermal research models.

Direct cellular uptake via PEPT1 transporter

An important pharmacokinetic detail separates KPV from larger anti-inflammatory peptides. KPV is small enough to be transported intact across cell membranes by PEPT1 — the di/tripeptide transporter expressed in intestinal epithelium and a number of other cell types [1]. PEPT1-mediated uptake means KPV can enter cells directly rather than acting only at cell-surface receptors. The published Dalmasso/Charrier/Merlin work documents this PepT1-mediated uptake explicitly as the pharmacokinetic basis for KPV anti-inflammatory effects in intestinal research models.

Independence from melanocortin receptors

Published research documents that KPV’s anti-inflammatory effects do not require melanocortin-receptor signaling. This is mechanistically distinct from alpha-MSH itself, which signals through MC1R–MC5R for both its pigmentary and a portion of its anti-inflammatory effects. KPV instead acts intracellularly — partly through PEPT1-mediated uptake, partly through direct NF-κB pathway modulation downstream of cellular entry [4]. The implication: KPV retains the anti-inflammatory pharmacophore of the parent hormone without engaging the melanocortin-receptor system.

Mast-cell and macrophage modulation

A complementary research line documents KPV effects on mast-cell degranulation and macrophage cytokine output in inflammation-model designs. Mast cells are central to acute and allergic inflammation; macrophages are central to chronic and tissue-level inflammation. KPV’s reported modulation of both cell types places it at multiple points in the inflammatory cascade rather than at a single receptor target.

Inflammatory bowel disease research

The most-cited KPV research line is in inflammatory bowel disease (IBD) animal models. Published research-animal-model literature — DSS colitis, TNBS colitis, IL-10 knockout mice — documents KPV oral or rectal administration reducing colonic inflammation, mucosal damage, and inflammatory cytokine expression in colon tissue [1] [2].

The mechanistic link is the PEPT1 transporter. PEPT1 is highly expressed in intestinal epithelium, and its expression is further upregulated at sites of intestinal inflammation. KPV taken up via intestinal PEPT1 reaches concentrations inside the inflamed enterocytes and macrophages where it can modulate NF-κB locally. The pharmacokinetic match between PEPT1 expression and the site of inflammation is what makes the gut a particularly relevant tissue for KPV research [6].

The Dalmasso, Charrier-Hisamuddin, Nguyen and Merlin lab work is the central published reference for this mechanism. Subsequent groups (Kannengiesser, Maaser, Heidemann and colleagues) have replicated the anti-colitis effects across multiple model systems.

Dermal and wound-healing research

The second major published KPV research line is in dermal inflammation and wound-bed remodelling. Published outcomes document KPV effects on dermal mast-cell degranulation, inflammatory-cytokine reduction in skin research models, and modulation of the mast-cell-driven component of cutaneous inflammation. This is the basis for KPV’s inclusion in the Klow Blend — the multi-compound research vial that combines:

• BPC-157 — pathway signaling (NO, VEGF, growth-hormone-receptor)
• TB-500 — G-actin sequestration and cell migration
• GHK-Cu — fibroblast signaling, collagen and matrix synthesis
• KPV — NF-κB anti-inflammatory and mast-cell modulation

The Klow rationale is straightforward: combine matrix synthesis (GHK-Cu), tissue migration and wound closure (TB-500), pathway signaling (BPC-157), and inflammation control (KPV) in a single multi-compound research vial. Each compound covers a different mechanism class.

Asthma and pulmonary research

A smaller but published KPV research line documents effects in airway-inflammation research models. The published work places KPV’s pulmonary effects downstream of the same NF-κB-modulating mechanism that drives the gut and dermal effects — airway epithelial and immune cells expressing PEPT1 are amenable to KPV uptake, with subsequent reduction in inflammatory cytokine output. The corpus here is meaningfully smaller than the IBD literature but is mechanistically consistent.

KPV in the Klow Blend context

KPV is the inflammation-control component of the Klow Blend. The four compounds cover distinct mechanism classes:

Compound	Mechanism class	Primary research line
BPC-157	Pathway signaling (NO / VEGF / GHR)	Tendon, ligament, mucosa repair
TB-500	G-actin sequestration	Cell migration, wound closure
GHK-Cu	Fibroblast signaling, gene expression	Dermal matrix, collagen synthesis
KPV	NF-κB anti-inflammatory	Mucosal and dermal inflammation control

Why KPV completes the Klow stack: BPC, TB and GHK directly drive synthesis, migration and signaling, but they do not directly cover the inflammation-control axis. KPV fills that gap. In a research design where the goal is to study combined matrix synthesis + tissue migration + inflammation control in a single vial, KPV adds the dimension that the other three compounds do not.

Storage and handling

KPV ships as lyophilized powder. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window (typically 24+ months).
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent.
• Reconstituted state: refrigerate at 2–8°C. Use within ~28 days under refrigeration.
• Avoid freeze-thaw cycles after reconstitution.

Each TogoPeptide KPV shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date, analysis date. See how to read a COA or reconstitution methodology for the methodology details.

Cross-research lines and pairings

• Klow Blend — multi-compound research vial: BPC-157 + TB-500 + GHK-Cu + KPV in one vial. The most common combined-peptide design covering signaling, migration, matrix synthesis and inflammation control simultaneously.
• Glow Stack: the curated three-tier skin-matrix bundle pairs GHK-Cu with the Klow Blend and SNAP-8 — useful when the research design needs both isolated GHK-Cu and the multi-compound matrix-and-inflammation context.
• Vial strengths: KPV ships at 5 mg or 10 mg per vial. Reconstitution math is documented in the reconstitution calculator.

Closing

KPV is the C-terminal tripeptide of alpha-MSH and the published “anti-inflammatory minimum sequence” of the parent hormone. Its mechanism is unusual among anti-inflammatory peptides: PEPT1-mediated cellular uptake delivers the tripeptide intracellularly, where it modulates NF-κB nuclear translocation directly — independently of melanocortin-receptor signaling. The dominant published research lines are in inflammatory bowel disease and dermal inflammation, with smaller pulmonary and mast-cell-modulation literatures.

This guide documents what published peer-reviewed research has investigated. It is mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source KPV for laboratory research:

• KPV product page — full identifiers, 5 mg / 10 mg vial, per-batch COA
• Klow Blend — pre-mixed BPC + TB + GHK-Cu + KPV combined-research design
• Glow Stack — curated 3-tier skin-matrix bundle (GHK-Cu + Klow Blend + SNAP-8)
• Skin-matrix research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.